Clinical trial · Observational
BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer
Association Between BRAF V600E and Redifferentiation Therapy in Patients With Radioiodine-refractory Papillary Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Papillary thyroid cancer (PTC) is the most common neoplasia in the thyroid gland. The combination of surgery, followed by radioiodine therapy (RIT) and thyroid-stimulating hormone (TSH) suppressive therapy is usually a curative option for differentiated thyroid cancer (DTC). Although DTC has a good prognosis generally, it is problematic when dedifferentiation is suspected and radioiodine refractoriness presumed. One possible therapy option for redifferentiation is the pretreatment with retinoids. From 2008 to 2014 there were 13 patients with PTC who were treated with retinoids after thyroidectomy before a further course of radioiodine. A recent study has shown that the efficacy of Selumetinib, another option for redifferentiation depends on the mutational status of the treated patient. In this retrospective study the investigators looked for a similar association between BRAF V600E and redifferentiation therapy with retinoids. As retinoids have fewer side effects compared to TKI, it is worth performing studies to assess the importance of genetic marker for the response and to estimate the chances of this specific patient collective. BRAF V600E seems to be associated with better long-term response after redifferentiation therapy with 13-cis RA in RAI-R PTC. Therefore, evaluation of BRAF mutational status prior to redifferentiation therapy could be beneficial for predicting response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Redifferentiation with retinoid acid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Radioiodine refractory papillary thyroid cancer
- description
- Patients with radioiodine refractory papillary thyroid cancer who received redifferentiation therapy with retinoid acid.
- interventionNames
- Drug: Redifferentiation with retinoid acid
- label
- Radioiodine sensitive papillary thyroid cancer
- description
- Patients who were in remission after one or two radioiodine therapies.
Primary outcomes (1)
- measure
- Response to radioiodine therapy after redifferentiation
- timeFrame
- 7 years
- description
- Redifferentiation therapy was performed using 13-cis RA (Isotretinoin, Roaccutan®) with a daily dose of orally 1,5mg/kg for up to two months. For assessment of clinical outcome of 13-cis retinoic acid treatment three parameters, tumor size, thyroglobulin levels and radioiodine uptake were considered in a graduated model.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 24 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Eligible criteria for radioiodine-refractory patients included: * PTC * no response to former RIT * decrease or loss of initial sufficient RI-Uptake * redifferentiation therapy with 13-cis-RA * available FFPE tissue. Eligible criteria for radioiodine-sensitive patients included: * PTC * cured after a maximum of two RIT * no redifferentiation therapy necessary * available FFPE tissue. Exclusion criteria * DTC other than PTC * patients lost to follow-up * other redifferentiation therapy than retinoids * anaplastic or medullary thyroid cancer * benign thyroid disease, no available FFPE tissue * more than two RITs in the control group * insufficient clinical information.
References
Publications (0)
Data not yet available